nach oben

Erschienen in:

01.05.2010 | Laboratory Investigation - Human/Animal Tissue

Tissue factor mediates the HGF/Met-induced anti-apoptotic pathway in DAOY medulloblastoma cells

verfasst von: Mathieu Provençal, Nancy Berger-Thibault, David Labbé, Ryan Veitch, Dominique Boivin, Georges-Étienne Rivard, Denis Gingras, Richard Béliveau

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

The classical treatment scheme for medulloblastoma (MB) is based on a tri-therapy approach consisting of surgical tumor resection, craniospinal axis radiation and chemotherapy. With current treatments relying mainly on non-specific cytotoxic therapy, a better understanding of the mechanisms underlying resistance to these treatments is important in order to improve their effectiveness. In this study, we report that stimulation of DAOY with HGF resulted in the protection of these cells against etoposide-induced apoptosis, this anti-apoptotic effect being correlated with an increase in the expression of tissue factor (TF), the initiator of the extrinsic pathway of coagulation. HGF-mediated protection from apoptosis was abolished by a c-Met inhibitor as well as by siRNA-mediated reduction of TF levels, implying a central role of Met-dependent induction of TF expression in this process. Accordingly, stimulation of DAOY with FVIIa, the physiological ligand of TF, also resulted in a significant protection from etoposide-mediated cytotoxicity. Overall, our results suggest the participation of the haemostatic system to drug resistance in MB and may thus provide novel therapeutic approaches for the treatment of these tumors.

Crawford JR, MacDonald TJ, Packer RJ (2007) Medulloblastoma in childhood: new biological advances. Lancet Neurol 6:1073–1085CrossRefPubMed

Rossi A, Caracciolo V, Russo G, Reiss K, Giordano A (2008) Medulloblastoma: from molecular pathology to therapy. Clin Cancer Res 14:971–976CrossRefPubMed

Grotzer MA, Janss AJ, Phillips PC, Trojanowski JQ (2000) Neurotrophin receptor TrkC predicts good clinical outcome in medulloblastoma and other primitive neuroectodermal brain tumors. Klin Padiatr 212:196–199CrossRefPubMed

Duplan SM, Theoret Y, Kenigsberg RL (2002) Antitumor activity of fibroblast growth factors (FGFs) for medulloblastoma may correlate with FGF receptor expression and tumor variant. Clin Cancer Res 8:246–257PubMed

Gilbertson RJ, Clifford SC, MacMeekin W, Meekin W, Wright C, Perry RH, Kelly P, Pearson AD, Lunec J (1998) Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma. Cancer Res 58:3932–3941PubMed

MacDonald TJ, Brown KM, LaFleur B, Peterson K, Lawlor C, Chen Y, Packer RJ, Cogen P, Stephan DA (2001) Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 29:143–152CrossRefPubMed

Gilbertson RJ, Clifford SC (2003) PDGFRB is overexpressed in metastatic medulloblastoma. Nat Genet 35:197–198CrossRefPubMed

Hartmann W, Koch A, Brune H, Waha A, Schuller U, Dani I, Denkhaus D, Langmann W, Bode U, Wiestler OD, Schilling K, Pietsch T (2005) Insulin-like growth factor II is involved in the proliferation control of medulloblastoma and its cerebellar precursor cells. Am J Pathol 166:1153–1162PubMed

Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915–925CrossRefPubMed

10.

Goumnerova LC (1996) Growth factor receptors and medulloblastoma. J Neurooncol 29:85–89CrossRefPubMed

11.

Li Y, Lal B, Kwon S, Fan X, Saldanha U, Reznik TE, Kuchner EB, Eberhart C, Laterra J, Abounader R (2005) The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. Cancer Res 65:9355–9362CrossRefPubMed

12.

Li Y, Guessous F, Johnson EB, Eberhart CG, Li XN, Shu Q, Fan S, Lal B, Laterra J, Schiff D, Abounader R (2008) Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma. Lab Invest 88:98–111CrossRefPubMed

13.

Benvenuti S, Comoglio PM (2007) The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 213:316–325CrossRefPubMed

14.

Wang X, Le P, Liang C, Chan J, Kiewlich D, Miller T, Harris D, Sun L, Rice A, Vasile S, Blake RA, Howlett AR, Patel N, McMahon G, Lipson KE (2003) Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther 2:1085–1092PubMed

15.

Abounader R, Laterra J (2005) Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol 7:436–451CrossRefPubMed

16.

Bowers DC, Fan S, Walter KA, Abounader R, Williams JA, Rosen EM, Laterra J (2000) Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. Cancer Res 60:4277–4283PubMed

17.

Boccaccio C, Sabatino G, Medico E, Girolami F, Follenzi A, Reato G, Sottile A, Naldini L, Comoglio PM (2005) The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 434:396–400CrossRefPubMed

18.

Provençal M, Labbé D, Veitch R, Boivin D, Rivard GE, Sartelet H, Robitaille Y, Gingras D, Béliveau R (2009) C-Met activation in medulloblastoma induces tissue factor expression and activity: effects on cell migration. Carcinogenesis 30(7):1089–1096

19.

Price GC, Thompson SA, Kam PC (2004) Tissue factor and tissue factor pathway inhibitor. Anaesthesia 59:483–492CrossRefPubMed

20.

Ott I, Weigand B, Michl R, Seitz I, Sabbari-Erfani N, Neumann FJ, Schomig A (2005) Tissue factor cytoplasmic domain stimulates migration by activation of the GTPase Rac1 and the mitogen-activated protein kinase p38. Circulation 111:349–355CrossRefPubMed

21.

Belting M, Dorrell MI, Sandgren S, Aguilar E, Ahamed J, Dorfleutner A, Carmeliet P, Mueller BM, Friedlander M, Ruf W (2004) Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 10:502–509CrossRefPubMed

22.

Versteeg HH, Spek CA, Richel DJ, Peppelenbosch MP (2004) Coagulation factors VIIa and Xa inhibit apoptosis and anoikis. Oncogene 23:410–417CrossRefPubMed

23.

Holen T, Amarzguioui M, Wiiger MT, Babaie E, Prydz H (2002) Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor. Nucleic Acids Res 30:1757–1766CrossRefPubMed

24.

Jiang X, Guo YL, Bromberg ME (2006) Formation of tissue factor-factor VIIa-factor Xa complex prevents apoptosis in human breast cancer cells. Thromb Haemost 96:196–201PubMed

25.

Fang J, Gu L, Zhu N, Tang H, Alvarado CS, Zhou M (2008) Tissue factor/FVIIa activates Bcl-2 and prevents doxorubicin-induced apoptosis in neuroblastoma cells. BMC Cancer 8:69CrossRefPubMed

26.

Fan S, Wang JA, Yuan RQ, Rockwell S, Andres J, Zlatapolskiy A, Goldberg ID, Rosen EM (1998) Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents. Oncogene 17:131–141CrossRefPubMed

27.

Guan M, Jin J, Su B, Liu WW, Lu Y (2002) Tissue factor expression and angiogenesis in human glioma. Clin Biochem 35:321–325CrossRefPubMed

28.

Hamada K, Kuratsu J, Saitoh Y, Takeshima H, Nishi T, Ushio Y (1996) Expression of tissue factor in glioma. Noshuyo Byori 13:115–118PubMed

29.

Ueno T, Toi M, Koike M, Nakamura S, Tominaga T (2000) Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer 83:164–170CrossRefPubMed

30.

Goldin-Lang P, Tran QV, Fichtner I, Eisenreich A, Antoniak S, Schulze K, Coupland SE, Poller W, Schultheiss HP, Rauch U (2008) Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis. Oncol Rep 20:123–128PubMed

31.

Bromberg ME, Sundaram R, Homer RJ, Garen A, Konigsberg WH (1999) Role of tissue factor in metastasis: functions of the cytoplasmic and extracellular domains of the molecule. Thromb Haemost 82:88–92PubMed

32.

Osterholm C, Li S, Ekberg H, Hedner U, Holgersson J (2008) Downregulation of tissue factor (TF) by RNA interference induces apoptosis and impairs cell survival of primary endothelium and tumor cells. Cell Tissue Res 334(1):93–102

33.

Rao LV (1992) Tissue factor as a tumor procoagulant. Cancer Metastasis Rev 11:249–266CrossRefPubMed

34.

Rao LV, Pendurthi UR (2005) Tissue factor-factor VIIa signaling. Arterioscler Thromb Vasc Biol 25:47–56PubMed

35.

Koizume S, Jin MS, Miyagi E, Hirahara F, Nakamura Y, Piao JH, Asai A, Yoshida A, Tsuchiya E, Ruf W, Miyagi Y (2006) Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII. Cancer Res 66:9453–9460CrossRefPubMed

36.

Ruf W (2001) Molecular regulation of blood clotting in tumor biology. Haemostasis 31(Suppl 1):5–7PubMed

37.

Luo W, Wang Y, Reiser G (2007) Protease-activated receptors in the brain: receptor expression, activation, and functions in neurodegeneration and neuroprotection. Brain Res Rev 56:331–345CrossRefPubMed

38.

Shieh SY, Ikeda M, Taya Y, Prives C (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325–334CrossRefPubMed

39.

Castellino RC, De Bortoli M, Lu X, Moon SH, Nguyen TA, Shepard MA, Rao PH, Donehower LA, Kim JY (2008) Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neurooncol 86:245–256CrossRefPubMed

40.

Li C, Colman LM, Collier ME, Dyer CE, Greenman J, Ettelaie C (2006) Tumour-expressed tissue factor inhibits cellular cytotoxicity. Cancer Immunol Immunother 55:1301–1308CrossRefPubMed

41.

Sakata T, Kario K, Matsuo T, Katayama Y, Matsuyama T, Kato H, Miyata T (1995) Suppression of plasma-activated factor VII levels by warfarin therapy. Arterioscler Thromb Vasc Biol 15:241–246PubMed

42.

Falanga A, Levine MN, Consonni R, Gritti G, Delaini F, Oldani E, Julian JA, Barbui T (1998) The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: results from a randomized trial. Thromb Haemost 79:23–27PubMed

43.

Ornstein DL, Meehan KR, Zacharski LR (2002) The coagulation system as a target for the treatment of human gliomas. Semin Thromb Hemost 28:19–28CrossRefPubMed

Titel: Tissue factor mediates the HGF/Met-induced anti-apoptotic pathway in DAOY medulloblastoma cells
verfasst von: Mathieu Provençal
Nancy Berger-Thibault
David Labbé
Ryan Veitch
Dominique Boivin
Georges-Étienne Rivard
Denis Gingras
Richard Béliveau
Publikationsdatum: 01.05.2010
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2010
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-009-0041-z

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

Specific chromosomal imbalances as detected by array CGH in ependymomas in association with tumor location, histological subtype and grade

Can permeability measurements add to blood volume measurements in differentiating tumefactive demyelinating lesions from high grade gliomas using perfusion CT?

Methotrexate-induced myelopathy responsive to substitution of multiple folate metabolites

Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma

Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value